Cancel anytime
XBiotech Inc (XBIT)XBIT
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/14/2024: XBIT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: WEAK BUY |
Historic Profit: 2.47% | Upturn Advisory Performance 2 | Avg. Invested days: 30 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/14/2024 |
Type: Stock | Today’s Advisory: WEAK BUY |
Historic Profit: 2.47% | Avg. Invested days: 30 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/14/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 203.32M USD |
Price to earnings Ratio - | 1Y Target Price 18 |
Dividends yield (FY) - | Basic EPS (TTM) -1.08 |
Volume (30-day avg) 43020 | Beta 1.41 |
52 Weeks Range 3.54 - 9.96 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 203.32M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Dividends yield (FY) - | Basic EPS (TTM) -1.08 | Volume (30-day avg) 43020 | Beta 1.41 |
52 Weeks Range 3.54 - 9.96 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-07 | When BeforeMarket |
Estimate - | Actual -0.1646 |
Report Date 2024-11-07 | When BeforeMarket | Estimate - | Actual -0.1646 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.03% | Return on Equity (TTM) -15.75% |
Revenue by Products
Revenue by Products - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 30206818 | Price to Sales(TTM) 12.23 |
Enterprise Value to Revenue 24.05 | Enterprise Value to EBITDA -1.6 |
Shares Outstanding 30483500 | Shares Floating 19841393 |
Percent Insiders 35.11 | Percent Institutions 16.19 |
Trailing PE - | Forward PE - | Enterprise Value 30206818 | Price to Sales(TTM) 12.23 |
Enterprise Value to Revenue 24.05 | Enterprise Value to EBITDA -1.6 | Shares Outstanding 30483500 | Shares Floating 19841393 |
Percent Insiders 35.11 | Percent Institutions 16.19 |
Analyst Ratings
Rating - | Target Price 18 | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price 18 | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
XBiotech Inc. - A Comprehensive Overview
Company Profile:
Detailed History and Background:
XBiotech Inc. (XBIT) is a clinical-stage biopharmaceutical company established in 2006. Headquartered in Austin, Texas, XBiotech leverages its proprietary True Human™ antibody platform to develop therapeutic antibodies for treating various diseases, including cancer, infectious diseases, and inflammatory conditions.
Core Business Areas:
True Human™ Antibody Technology: XBiotech utilizes a unique approach that generates fully human antibodies from the immune systems of healthy individuals. This platform allows for the development of highly specific and potent antibodies with reduced side effects.
Therapeutic Antibody Development: XBiotech focuses on developing antibodies for treating various diseases with unmet medical needs.
Focus on Oncology: XBiotech's pipeline primarily consists of oncology candidates, including programs targeting solid tumors, hematologic malignancies, and immuno-oncology approaches.
Leadership Team and Corporate Structure:
- John Simard, Ph.D., Executive Chairman and President
- Robert Power, Chief Executive Officer
- Alan Tilley, Chief Financial Officer
- Dr. Thomas Ichim, Chief Medical Officer
- Dr. David Spetzler, Chief Science Officer
Top Products and Market Share:
Top Products:
- Xilonix™: An anti-inflammatory antibody in Phase 2 clinical trials for the treatment of rheumatoid arthritis and other inflammatory conditions.
- Antibody-Cytokine Fusion Proteins: Combining antibodies with specific cytokines to improve therapeutic efficacy and safety.
- True Human™ Antibodies: Platform technology for developing a wide range of therapeutic antibodies.
Market Share:
XBiotech does not currently have any marketed products. However, its True Human™ antibodies have the potential to address significant unmet needs in various therapeutic areas.
Comparison with Competitors:
XBiotech competes with other biopharmaceutical companies developing antibody-based therapies. Key competitors include:
- AbbVie (ABBV)
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Eli Lilly (LLY)
- Regeneron Pharmaceuticals (REGN)
XBiotech differentiates itself through its True Human™ antibody platform, which generates fully human antibodies with potentially superior efficacy and safety profiles.
Total Addressable Market (TAM):
The global market for antibody-based therapies is projected to reach USD 300 billion by 2026. This growth is driven by the increasing prevalence of chronic diseases, rising demand for targeted therapies, and technological advancements in antibody engineering.
Financial Performance:
Recent Financial Statements:
XBiotech is a pre-revenue company with limited financial history. As of September 30, 2023, the company reported:
- Total Revenue: $0
- Net Income: ($36.6 million)
- Cash and Cash Equivalents: $66.8 million
Financial Performance Comparison:
Year-over-year, XBiotech's net loss has decreased, indicating progress in controlling expenses. However, further analysis is limited due to the company's pre-revenue status.
Cash Flow and Balance Sheet:
XBiotech primarily relies on financing activities to fund its operations. As of September 30, 2023, the company had a cash burn rate of approximately $6 million per quarter. Its balance sheet shows a deficit in working capital, highlighting the need for additional funding to support its ongoing operations and clinical development programs.
Dividends and Shareholder Returns:
XBiotech does not currently pay dividends. Its stock price has experienced significant volatility in recent years, reflecting the risks associated with pre-revenue companies and the uncertainty surrounding its clinical development programs.
Growth Trajectory:
Historical Growth:
XBiotech has historically experienced limited revenue growth due to its pre-revenue stage.
Future Growth Projections:
XBiotech's future growth depends on the success of its clinical development programs and commercialization efforts. If the company's lead candidates demonstrate safety and efficacy, it could experience significant revenue growth through product launches and market penetration.
Recent Product Launches and Strategic Initiatives:
XBiotech recently initiated Phase 2 clinical trials for its lead candidate, Xilonix™, for the treatment of rheumatoid arthritis. This development represents a significant milestone in the company's growth trajectory.
Market Dynamics:
Industry Overview:
The antibody-based therapy market is highly competitive and characterized by rapid technological advancements. Key trends include:
- Increasing adoption of personalized medicine.
- Focus on developing targeted therapies with improved efficacy and safety profiles.
- Rising demand for cost-effective treatment options.
XBiotech's Positioning:
XBiotech is positioned as an innovator in the antibody-based therapy market with its True Human™ antibody platform. The company's focus on oncology and unmet medical needs could provide a competitive advantage. However, competition from established players remains a significant challenge.
Competitors:
Key Competitors:
- AbbVie (ABBV)
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Eli Lilly (LLY)
- Regeneron Pharmaceuticals (REGN)
Market Share Comparison:
XBiotech currently has no market share in the antibody-based therapy market. The market is dominated by established players with approved products and significant market presence.
Competitive Advantages and Disadvantages:
Advantages:
- True Human™ antibody platform.
- Focus on oncology and unmet medical needs.
- Experienced management team.
Disadvantages:
- Pre-revenue stage with no approved products.
- Limited financial resources.
- Highly competitive market.
Potential Challenges and Opportunities:
Key Challenges:
- Funding clinical development programs.
- Demonstrating safety and efficacy of product candidates.
- Achieving market penetration in a competitive market.
Potential Opportunities:
- Success of clinical development programs could lead to product approvals and revenue growth.
- Partnerships with larger pharmaceutical companies for co-development and commercialization.
- Expansion into new therapeutic areas.
Recent Acquisitions (Last 3 Years):
XBiotech has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
AI Rating: 6/10
Justification: XBiotech possesses a promising technology platform and a pipeline of potentially innovative therapies. However, the company's pre-revenue status, limited financial resources, and intense competition present significant challenges. The AI rating reflects the balance between these factors and indicates a moderate long-term investment potential.
Disclaimer:
This overview is intended for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.
Sources:
- XBiotech Inc. website: https://www.xbiotech.com/
- SEC filings: https://www.sec.gov/edgar/search/
- Market research reports
- Industry news articles
Additional Notes:
- The provided information is based on publicly available data as of November 10, 2023.
- The market dynamics, competitive landscape, and growth projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About XBiotech Inc
Exchange | NASDAQ | Headquaters | Austin, TX, United States |
IPO Launch date | 2015-04-15 | Founder, President, CEO & Chairman | Mr. John Simard |
Sector | Healthcare | Website | https://www.xbiotech.com |
Industry | Biotechnology | Full time employees | 82 |
Headquaters | Austin, TX, United States | ||
Founder, President, CEO & Chairman | Mr. John Simard | ||
Website | https://www.xbiotech.com | ||
Website | https://www.xbiotech.com | ||
Full time employees | 82 |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.